Pfizer CEO Albert Bourla said the company could release data on whether the vaccine was working or not as early as this month, but the company said in a presentation that it was an independent data monitoring board that would determine whether a trial had been successful or not. conducted a provisional efficacy analysis.
The company also reported a 4.3% drop in third-quarter sales, caused by increased competition for the non-patent painkiller Lyrica and lower demand for some of its treatments during the COVID-19 pandemic.
Pfizer said Lyrica’s quarterly sales fell 33% to $ 352 million.
Total sales fell to $ 12.13 billion from $ 12.68 billion last year.
As the crimps pandemic demands specific Pfizer therapies and ravages the global economy, investors are very focused on looking at the final stage study data of the vaccine candidate being developed with BioNTech.